TFAP2A enhances radioresistance of non-small cell lung cancer by transcriptionally activating BRCA1
The TFAP2A/BRCA1 axis may serve as a predictive biomarker and therapeutic target for overcoming radioresistance, and TFAP2A-targeted radiosensitization warrants further preclinical development.